Cyanotech Corporation

CYAN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-3.2M $-5.3M $-3.4M $2.2M $920.0K $387.0K $-3.6M $1.0M
Depreciation & Amortization $1.5M $1.6M $1.7M $1.6M $1.7M $1.9M $1.9M $1.9M
Depreciation — — — — — — — —
Amortization — — — — — — — —
Stock-Based Compensation $247.0K $359.0K $310.0K $344.0K $214.0K $577.0K $322.0K $400.0K
Net Cash from Operating Activities $-1.2M $-455.0K $-2.1M $2.4M $2.4M $1.2M $-847.0K $1.5M
Investing Activities
Capital Expenditures — — — — — — $431.0K $1.0M
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $-247.0K $-381.0K $-1.1M $-1.3M $-760.0K $-224.0K $-531.0K $-1.0M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $990.0K $569.0K $1.6M $-2.3M $-290.0K $558.0K $824.0K $-498.0K
Net Change in Cash $-450.0K $-267.0K $-1.6M $-1.2M $1.4M $1.6M $-554.0K $-78.0K
Free Cash Flow — — — — — — $-1.3M $485.0K
← Newer Page 1 of 2 Older →